The ultimate aid to reduce respiratory stress

Natural Solutions

Aflorin® P L

Factors that influence the development of respiratory diseases

1. The animal: age, species and genetics, all play a major role determining how sensitive or resistant the animal may be towards the pathogen.

2. The environment: environmental temperature, dust, gases, humidity, poor ventilation, play also a major role on the occurrence of respiratory irritations. Physical vectors such as rats, insects and wild birds can bring in pathogens, whereas stress reduces the immunity of the animals. In addition, poor management practices can also influence respiratory diseases, including visitors, number and mixing of animals.

3. The pathogen itself: respiratory diseases can be caused by bacteria (e.g. pathogenic E. coli), viruses (e.g. pneumovirus) and fungi (e.g. Aspergilosis). Also mycoplasma is responsible for a broad range of infections. They have as well virus as bacterial properties. Seldom a respiratory disease is associated with only one pathogen. In the majority of the cases, both pri-mary and secondary infections are seen. Secondary (bacterial) infections often lead to high mortality.

4. Housing density: more intensive production is responsible for the increase in respiratory problems.

5. Ammonia: ammonia and ammonia gasses – which are always present in poultry houses – are irritant and corrosive, and may be harmful by all routes of exposure. Acute oral exposure rapidly results in pain, excessive salivation and burn to the mouth, throat and esophagus. Acute inhalation may initially cause upper respiratory tract irritation. Substantial exposures can cause burns in the oral cavity, nasopharynx, larynx and trachea, together with airway obstruction, respiratory distress and bronchiolar and alveolar oedema.

Aflorin® P L

Several common and important diseases can affect the respiratory system (air passages, lungs, air sacs) of poultry.

Diseases of the respiratory tract account for a significant percentage of the overall disease incidence in poultry. Often, a respiratory disease observed in a flock will be part of a multi systemic disease whereby the total impact is defined by a variety of pathogens, environmental factors and the immune status of the animal.

Modern intensive poultry production is susceptible to high economic losses from disease outbreaks due to the high con-centration and genetic uniformity of animals present. Newcastle disease, salmonellosis, and avian influenza are three poultry diseases of high economic and/or human safety concern.

The ultimate aid to reduce respiratory stress

BETTER PERFORMACE

HIGHER FEED AND WATER INTAKE

HIGHER OXIGENE LEVEL

RESPIRATORY HEALTH

INCREASE OF VITALITY AND COMFORT

Consequences of respiratory infections

• Reduced growth performance, up to 40%

• Reduced immunity

• Incomplete recovery, tissue can be severely damaged resulting in more sensitive animal for the rest of the production period

• Mortality

www.innovad-global.com

Aflorin® P L

Essential oils are mixtures of compounds characterized by their capacity to generate flavour or aroma, generally obtained from spices, aromatic herbs, fruits, and flowers. Terpenoids are the most abundant compounds in essential oils and are present either as hemiterpenes, monoterpenes and sesquiterpens or as their derivatives.

Composition of Aflorin® P L

Aflorin® P L benefits

• Improves respiration and air passage

• Reduces mucus accumulation and improves discharge from the respiratory cavities

• Reduces the negative effects of diseases and improves quick recovery

• Reduces stress and loss of valuable feed intake

• Improves resistance to all respiratory infections

• Reduces the negative effects and stress of live vaccinations

• Improves survivability and reduces mortality

Dosage and application

Drinking water: at the rate of 200ml/1000l via batch treatment or dosing system

By coarse spray: 200ml/10l of water, sprayed for 20,000 chicks

Poultry: use at the rate of 1ml/kg bodyweight (twice a day) for 3 days

• Use after vaccination for 3 days (recommended to withdraw Aflorin® P L 1 day prior or 2 days post live vaccination and to not mix with vaccines)

• Use in case of CRD for 3 days

• Application should be ideally twice daily

O2

Menthol

• Volatile• Soothing• Antibacterial• Stimulant• Facilitates easy breathing• Reduce mucus inflammation

Eucalyptus

• Antibacterial• Aids bronchi exhalation• Antiviral• Improves respiratory health• Aids mucus excretion

from sinus

Plant sterols Saponin

• Emulsifier• Bind free ammonia from air• Improve absorption of active

compound• Help on dispersing particles• Aid quick recovery

Effects of Aflorin® P L on decreasing respiratory clinical signs and ammonia production in poultry flocks, Iran, 2015

Facts:

– 24.000 one day old Ross strain broiler chicks

– 3 groups of 8.000 chicks each, similar conditions and vaccination program

– Treatment 72 hours after administration of vaccinesA: Aflorin® P LB: Competitor productC: Control

Method of measuring:

Calculation: (° 1st observed lesion * #days lesion was observed) + (° 2nd observed lesion * #days lesion was observed) + …

* General lesions to describe the severity of respiratory clinical signs: 0: no clinical signs 1: mild respiratory noise 2: presence of respiratory noise and lacrimal discharges 3: cough and sneezing 4: increase of mortality rate (n° of carcasses)

** General histopathological lesions on 5 trachea samples of each group: 0: no lesion 1: cilia degeneration 2: increasing the goblet cell numbers and mucus 3: mild infiltration of inflammatory cells 4: severe infiltration of inflammatory cells

The bigger the number, the more severe are the lesions.

Fig. 1: Comparison of severity of respiratory clinical signs and histopathological lesions (72 hours after observing respiratory clinical signs) in different experimental groups.

Fig. 2: Comparison of the total function’s mean in different experimented groups.

© 2

018

by In

nova

d®. A

ll rig

hts

rese

rved

. 30.

10.2

018

Trial

Innovad nv/saSales & Customer Services : Cogels Osylei 33, 2600 Berchem, BELGIUMProduction & Laboratory : Postbaan 69, 2910 Essen, BELGIUMTel. +32(0) 3 667 16 55www.innovad-global.com info@innovad-global.com

Innovad® Laboratories is a division of Innovad® nv/sa

GROUP A B C

Severity of clinical respiratory signs* 603 611 724

Severity of histopathological lesions** 14 17 27

A B C

Mortality rate 7,80 7,90 8,40

Ammonia-producing bacteria 3 5 5

NDHI antibody titer at the end of the trial period

6,43 6,31 6,10

AIHI antibody titer at the end of the trial period

7,27 7,13 7,20

IBELISA antibody titer at the end of the trial period

4985 4713 4576

ND: Newcastle diseaseAI: Avian influenzaIB: Infectious bronchitisHI: Hemagglutination-inhibitionELISA: Enzyme-linked immunosorbent assay

Conclusion:

Preventive use of Aflorin® P L around vaccination positively influences antibody titers and reduces clinical

respiratory signs and histopathological lesions.